Circulating Tumor Cells and Treatment De-escalation After Neoadjuvant Therapy for HER2 Positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|HER2-positive Breast Cancer|Circulating Tumor Cell
Interventions: DRUG: Pertuzumab|DRUG: Trastuzumab|OTHER: Circulating tumor cells
Sponsor: AC Camargo Cancer Center